Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
about
Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity aDenosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.CT-P13 in the treatment of rheumatoid arthritis.bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search.What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice.Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations.A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study.Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study.Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritRheumatoid arthritis: DMARD de-escalation - let the patient guide you.Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis.Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial.Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort studyRedox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid ArthritisNatural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome
P2860
Q33688001-30379B37-3489-4476-A4C4-13265B6478D9Q33730950-5DE0C18C-4141-41A6-B075-8273CFA6234CQ34545263-0376E0B1-C090-4E0A-83D0-CB5DD9D1E7ADQ36151778-6F4D75DC-012E-47A6-95CF-5CDCD684D7A5Q38676104-4D0A9006-FD17-4015-8F83-ACA643B2CF94Q38751251-7D08F31B-73F6-4AC4-9940-AB2A431E5FDDQ38955830-B7D60693-730C-4CA4-95F4-1BBCDDD80313Q39023180-E1D791F9-8FF4-4DF6-94BD-4A43F9C6916CQ42021846-F0822C5D-CDD1-4678-8FA9-94CFC6015E08Q42273153-B2246EFA-A5DF-4705-A39C-0491E9A74642Q46930972-A224B146-62EE-4874-AD30-5E98438D54FDQ47097484-F42CF0D9-21BF-44CC-B407-23D04014F824Q47102960-27E9CF3A-5F6B-4854-BEB6-1FA9EB950CB6Q47632929-15C8CBAD-C87C-4CA9-805F-9827F9733A70Q47687442-1306C5D3-2EFC-48AE-98C9-5F3DD4E8BE54Q50594712-0AA4DB0D-3BF7-41A5-9270-A95CA7BDAB71Q50729871-233125D8-E241-4CAC-9B60-E082A980F8ABQ52562516-0131C419-8F87-4D61-A597-7CC4A0420FB6Q53118278-EFA77CE6-2C15-4AB6-984E-FC783BE62861Q54967304-7414F5DF-932D-4092-A8EB-B738DED100FAQ55191136-34E70071-EC5B-4048-8DB0-42D69E64DAABQ55223606-8088A303-CFB0-45E3-815E-D0F75A858783Q56890364-EBCD830D-F3AA-4BC9-B148-09C0ADF80C78Q57072691-7D312017-3ABE-41CF-8237-5B5E4C3B6F81Q58703927-572AC535-F1AB-475E-A477-4BBB90559C92
P2860
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Tapering biologic and conventi ...... vidence and future directions.
@ast
Tapering biologic and conventi ...... vidence and future directions.
@en
Tapering biologic and conventi ...... vidence and future directions.
@en-gb
type
label
Tapering biologic and conventi ...... vidence and future directions.
@ast
Tapering biologic and conventi ...... vidence and future directions.
@en
Tapering biologic and conventi ...... vidence and future directions.
@en-gb
prefLabel
Tapering biologic and conventi ...... vidence and future directions.
@ast
Tapering biologic and conventi ...... vidence and future directions.
@en
Tapering biologic and conventi ...... vidence and future directions.
@en-gb
P2093
P2860
P50
P1154
2-s2.0-84973311826
P1476
Tapering biologic and conventi ...... vidence and future directions.
@en
P2093
David S Pisetsky
Gerd Burmester
Yoshiya Tanaka
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-209201
P407
P5530
P577
2016-06-03T00:00:00Z
P6179
1033174330